By continuing on our website, you agree to our use of the cookie for statistical and personalization purpose.
Large pharmaceutical companies say allowing Medicare to negotiate lower drug prices will stifle innovation in drug development. Read a new op-ed in Harvard Business Review to find out why that’s not so.
Director, Maya Angelou Research Center on Minority Health, Wake Forest University
Other Publication / Mar 01, 2008